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Abstract
 
The promyelocytic leukemia (PML) gene encodes a putative tumor suppressor gene involved
in the control of apoptosis, which is fused to the retinoic acid receptor 
 
a
 
 (RAR
 
a
 
) gene in the
vast majority of acute promyelocytic leukemia (APL) patients as a consequence of chromo-
somal translocations. The PMLRAR
 
a
 
 oncoprotein is thought to antagonize the function of
PML through its ability to heterodimerize with and delocalize PML from the nuclear body. In
APL, this may be facilitated by the reduction to heterozygosity of the normal PML allele. To
determine whether PML acts as a tumor suppressor in vivo and what the consequences of de-
regulated programmed cell death in leukemia and epithelial cancer pathogenesis are, we crossed
PML
 
2
 
/
 
2
 
 mice with human cathepsin G (hCG)-PMLRAR
 
a
 
 or mammary tumor virus
(MMTV)/neu transgenic mice (TM), models of leukemia and breast cancer, respectively. The
progressive reduction of the dose of PML resulted in a dramatic increase in the incidence of
leukemia, and in an acceleration of leukemia onset in PMLRAR
 
a
 
 TM. By contrast, PML in-
activation did not affect neu-induced tumorigenesis. In hemopoietic cells from PMLRAR
 
a
 
TM, PML inactivation resulted in impaired response to differentiating agents such as RA and
vitamin D
 
3
 
 as well as in a marked survival advantage upon proapoptotic stimuli. These results
demonstrate that: (a) PML acts in vivo as a tumor suppressor by rendering the cells resistant to
proapoptotic and differentiating stimuli; (b) PML haploinsufficiency and the functional impair-
ment of PML by PMLRAR
 
a
 
 are critical events in APL pathogenesis; and (c) aberrant control
of programmed cell death plays a differential role in solid tumor and leukemia pathogenesis.
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Introduction
 
Acute promyelocytic leukemia (APL),
 
1
 
 a distinct subtype
of acute myelogenous leukemia (AML), accounts for
 
.
 
10% of all AMLs and is characterized by: (a) the accumu-
lation of leukemic cells with promyelocytic features in the
bone marrow (BM); (b) the invariable association with
chromosomal translocations involving the retinoic acid re-
ceptor 
 
a
 
 (RAR
 
a
 
) locus in chromosome 17; and (c) the ex-
quisite sensitivity of the APL blasts to the differentiating
action of the RA (1–3). In the vast majority of cases,
RAR
 
a
 
 fuses to the promyelocytic leukemia (PML) gene as
a consequence of a reciprocal and balanced translocation
between chromosomes 15 and 17 (t[15;17]; reference 2).
PML belongs to a family of proteins characterized by the
presence of the RING-B-box-coiled-coil (RBCC) motif
(4), which consists of a C
 
3
 
HC
 
4
 
 zinc finger (RING finger)
and one or two additional Cys-rich regions (B-boxes) fol-
lowed by a predicted leucine coiled-coil region. The PML
coiled-coil domain is responsible for the formation of sta-
ble PML and PMLRAR
 
a
 
 homo- and heterodimers (5).
PML and PMLRAR
 
a
 
 heterodimerization results in the
delocalization of PML from discrete speckled nuclear
structures, the nuclear bodies (NBs). As a consequence, in
APL cells, PML acquires an aberrant microspeckled nuclear
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Abbreviations used in this paper: 
 
APL, acute promyelocytic leukemia;
BM, bone marrow; hCG, human cathepsin G; LFS, leukemia-free sur-
vival; MMTV, mammary tumor virus; NB, nuclear body; PML, promy-
elocytic leukemia; RA, retinoic acid; RXR, retinoid X receptor; TFS,
tumor-free survival; TM, transgenic mice; TUNEL, terminal deoxynu-
cleotidyl transferase–mediated uridine triphosphate end labeling; VDR,
vitamin D receptor; WT, wild-type. 
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localization pattern (6). This observation has led to the hy-
pothesis that the function of PML is deregulated in the
presence of the PMLRAR
 
a
 
 fusion oncoprotein (1, 2, 6).
In vitro experiments have shown that PML can act as a
tumor suppressor (6–9). PML can inhibit transformation
induced by neu (c-erbB2, ERBB2), Ha-ras, mutant p53,
Ha-ras plus c-myc in NIH3T3, and rat fibroblasts (7–9). In
fibroblasts, PML is involved in the regulation of p53-
dependent senescence upon oncogenic transformation (10).
PML also plays a role in multiple apoptotic pathways (11).
PML
 
2
 
/
 
2
 
 mice and cells are protected from multiple
caspase-dependent apoptotic signals such as Fas, TNF,
ceramide, IFNs, and ionizing radiation (11). PML
 
2
 
/
 
2
 
 mice
developed a greater number of skin papillomas when topi-
cally challenged with 12-
 
O
 
-tetradecanoylphorbol-13-ace-
tate (TPA) and dimethybenzanthracene (DMBA [12]). In a
second model, DMBA was injected into the salivary glands,
which lead to a greater number of B and T lymphomas in
PML
 
2
 
/
 
2
 
 mice than the wild-type (WT) controls (12).
However, the fact that PML
 
2
 
/
 
2
 
 mice succumbed to infec-
tions severely compromised the long-term assessment of
tumor incidence, whereas the incidence of spontaneous tu-
mors in the PML
 
2
 
/
 
2
 
 cohort was not increased during the
first year of life (12). Moreover, the fact that PML
 
2
 
/
 
2
 
 mice
develop tumors only when challenged with carcinogens
casts doubts on the relevance of PML in tumor suppression.
Therefore, it remains to be determined whether, in vivo,
PML would act as a tumor suppressor in a relevant disease
context and, if that is the case, by which mechanisms PML
would antagonize tumorigenesis. Furthermore, in APL the
dose of PML is reduced to heterozygosity in view of the
fact that one allele is involved in the chromosomal translo-
cation. If indeed PML acts as a tumor suppressor in vivo,
this may dramatically enhance the oncogenic potential of
PMLRAR
 
a
 
, even more so if the oncoprotein can act as a
dominant negative on PML function. To address these
questions we studied whether, and through which mecha-
nisms, PML would antagonize PMLRAR
 
a
 
–induced leu-
kemogenesis and neu-induced breast tumorigenesis in hu-
man cathepsin G (hCG)-PMLRAR
 
a
 
 and mammary tumor
virus (MMTV)/neu transgenic mice (TM). We here report
that PML acts in vivo as a tumor suppressor through con-
trol of programmed cell death and cellular differentiation.
 
Materials and Methods
 
Generation and Genotyping of Mutant Mice.
 
The generation of
the PML
 
2
 
/
 
2
 
 mutants and hCG-PMLRAR
 
a
 
 TM has been de-
scribed elsewhere (12, 13). PML
 
2
 
/
 
2
 
 mice were mated with hCG-
PMLRAR
 
a
 
 TM to generate hCG-PMLRAR
 
a
 
/PML mutants of
six different genotypes. Similarly, we crossed TM harboring the
neu protooncogene under the control of the MMTV promoter
(The Jackson Laboratory [14]) with PML
 
2
 
/
 
2
 
 mice. PML mutants
were identified by Southern blot analysis of tail DNA using a
1-kb ApaI mouse PML fragment (probe A), as described previously
(12). MMTV/neu TM were identified also by Southern blot
analysis using a neu cDNA-specific probe (14). To distinguish
hCG-PMLRAR
 
a
 
 heterozygous (
 
1
 
/
 
2
 
) from hCG-PMLRAR
 
a
 
homozygous (
 
1
 
/
 
1
 
) mice, tail DNA was digested with EcoRI,
 
hybridized with a 250-bp HindIII-XbaI hCG genomic fragment
(probe CT), and cohybridized with a murine 2.3-kb BamHI p53
cDNA probe. The genotype of the TM was determined using a
PhosphorImager Densitometer (Bio-Rad Laboratories) based on
the comparative analysis of the intensity of p53 and hCG-PML-
RAR
 
a
 
 signals.
 
Follow Up of Mutant Mice.
 
hCG-PMLRAR
 
a
 
/PML mutants
were bled twice a month from the tail, and white blood cells
(WBCs), hemoglobin, and platelet counts were determined using
a Technicon H2 automated counter. The differential counts of
the peripheral blood (PB) were performed microscopically on
Wright-Giemsa stained smears. Diagnosis of leukemia was made
on the basis of the following concomitant criteria: (a) presence of
blasts/promyelocytes (
 
.
 
1%) in the PB; (b) leukocytosis (WBCs 
 
.
 
30 
 
3
 
 10
 
3
 
/
 
m
 
l); and (c) anemia (hemoglobin 
 
,
 
 10 g/dl) and/or
thrombocytopenia (platelets 
 
, 
 
500 
 
3
 
 10
 
3
 
/
 
m
 
l). The MMTV/
neu/PML mutants were inspected closely on a weekly basis for
the appearance of mammary tumors and/or a decline in overall
body condition. Animals were killed just before their natural de-
mise or when discomfort due to the tumor mass was observed.
Postmortem analysis was performed in all tissues, including mam-
mary glands, lungs, BM, spleen, liver, and lymph nodes.
 
Flow Cytometry.
 
The immunophenotype of PB, BM, and
spleen cells from leukemic hCG-PMLRAR
 
a
 
/PML mutants was
determined using the following fluorochrome-conjugated mAbs:
CD11b, Gr1, c-kit, Sca1, CD3, and CD45R/B220. Fluoro-
chrome conjugated isotypic Abs of irrelevant specificity were
used as controls. All Abs were obtained from BD PharMingen.
Samples were analyzed on a FACScan™ flow cytometer using
CellQuest™ software (Becton Dickinson).
 
In Vitro Methylcellulose Colony Assay.
 
5 
 
3
 
 10
 
4
 
 BM cells ob-
tained from 2–3-mo-old sex-age–matched mice of various geno-
types were cultured in methylcellulose and CFU-GM were
scored at day 7 as described previously (12). Three independent
experiments, each in triplicate, were carried out using one mouse
per genotype. RA (Sigma-Aldrich) in DMSO (Sigma-Aldrich)
was added at a final concentration of 100 nM, 1,25-dihydroxyvi-
tamin D
 
3
 
 (vitamin D
 
3
 
; Sigma-Aldrich) in ethanol was added at a
final concentration of 1 nM, and the anti-Fas mAb (clone Jo2;
BD PharMingen) in PBS was added at a final concentration of
100 ng/ml. Negative controls included the incubation with the
respective vehicles and, for the experiments with anti-Fas mAb,
the addition of an irrelevant immunoglobulin of the same class
(BD PharMingen).
 
Assessment of Myeloid Differentiation and Apoptosis in Liquid Cul-
tures.
 
2 
 
3
 
 10
 
6
 
 BM cells from 2–3-mo-old sex-age–matched
mice of various genotypes were cultured in DMEM supple-
mented with 30% of FCS, 20 ng/ml GM-CSF, and 50 ng/ml
G-CSF. RA, vitamin D
 
3
 
, anti-Fas mAb, or their respective vehi-
cles, were added at the above mentioned concentrations. Myeloid
differentiation was assessed by determining the number of CD11b
 
1
 
cells after 72 h of incubation with RA or vitamin D
 
3
 
 by flow cy-
tometry. The percentage of apoptotic cells after 24 h of incubation
with the anti-Fas mAb was determined by staining the cells with an
anti–annexin V mAb and propidium iodide (PI) in combination
using the Apoptosis Detection Kit II (BD PharMingen).
 
In Vivo Detection of Apoptosis and Immunohistochemistry.
 
The
number of apoptotic cells in breast tumor paraffin sections (5 
 
m
 
m)
from MMTV/neu TM was scored by in situ terminal deoxynu-
cleotidyl transferase–mediated uridine triphosphate end labeling
(TUNEL) as described previously (15). Immune detection of
PML and Ki67 in frozen and paraffin breast tumor sections re-
spectively were performed as described (12, 16). 
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Statistical Analysis.
 
Statistical analysis was carried out using
the SPSS software (SPSS). Leukemia-free survival (LFS) and tu-
mor-free survival (TFS) analyses (dated from birth to diagnosis)
was based on Kaplan-Meyer estimation and groups were com-
pared by log-rank test. Differences in disease incidence were
evaluated using the Fisher’s exact test. The comparison between
the number of hemopoietic colonies, the percentage of CD11b
 
1
 
,
of Ki67
 
1
 
, and of apoptotic cells between the groups was per-
formed by the Mann-Whitney U test. All quoted
 
 P 
 
values are
two-sided, and confidence intervals refer to 95% boundaries.
 
Results and Discussion
 
TM expressing the PMLRAR
 
a
 
 fusion gene under the
control of the hCG-PMLRAR
 
a 
 
develop a form of leuke-
mia that closely resembles the human APL (13). However,
only 10–15% of these mice develop the disease after a long
latency period (
 
.
 
12 mo; reference 13), indicating that
PMLRAR
 
a
 
 is necessary, but not sufficient, to cause full-
blown leukemia. To determine whether PML inactivation
would accelerate leukemia onset and/or penetrance, we
crossed hCG-PMLRAR
 
a
 
 TM with PML
 
2
 
/
 
2
 
 mice. Com-
pared with hCG-PMLRAR
 
a
 
1
 
/
 
2
 
PML
 
1
 
/
 
1
 
 mice, hCG-
PMLRAR
 
a
 
1
 
/
 
2
 
PML
 
1
 
/
 
2
 
 or PML
 
2
 
/
 
2
 
 mutants presented a
significant decrease in the LFS (mean LFS 
 
6
 
 SD in hCG-
PMLRAR
 
a
 
1
 
/
 
2
 
/PML
 
1
 
/
 
1 mice: 686.4 6 35.5 d; hCG-
PMLRARa1/2PML1/2 mice: 498.9 6 31.3 d [P =
0.003]; hCG-PMLRARa1/2PML2/2 mice: 434.4 6
30.6 d [P , 0.0001]; Fig. 1 a). Moreover, the incidence of
Figure 1. PML inactivation leads to an in-
crease in frequency and an earlier leukemia onset
in hCG-PMLRARa TM. (a–d) hCG-PML-
RARa TM were mated with mice in which the
PML gene was disrupted by homologous recom-
bination. The various genotypes and the num-
bers of mice analyzed are indicated. LFS (in days)
was significantly shorter and leukemia frequency
higher in hCG-PMLRARa1/2PML2/2 and
hCG-PMLRARa1/2PML1/2 mice compared
with hCG-PMLRARa1/2PML1/1 mice (a).
The leukemia frequency was also increased in
hCG-PMLRARa1/1 mice compared with
hCG-PMLRARa1/2 mice either in PML1/1
(b), PML1/2 (c), or PML2/2 (d) backgrounds.
(e) Leukemic cells in all the studied groups
exhibited similar features. PB smears and
BM cytospin preparations from leukemic
hCG-PMLRARa1/2PML2/2 and hCG-
PMLRARa1/2PML1/1 mice were stained with
Wright-Giemsa stain. The arrows indicate the
leukemic cells. Original magnification: 31,000.524 PML in Tumor Suppression
leukemia in the first year of life was of 12.5% in hCG-
PMLRARa1/2PML1/1 mice, whereas in the hCG-
PMLRARa1/2PML1/2 and hCG-PMLRARa1/2PML2/2
mice it was of 31.1% (P , 0.001) and 53.1% (P , 0.001),
respectively (Fig. 1 a). The difference in the LFS between
hCG-PMLRARa1/2PML1/2 and hCG-PMLRARa1/2
PML2/2 mice was not statistically significant (P 5 0.21).
On the contrary, the incidence of leukemia was signifi-
cantly higher in the hCG-PMLRARa1/2PML2/2 mice
(P 5 0.003). Thus, PML inactivation dramatically contrib-
utes to APL leukemogenesis and the inactivation of one
PML allele has already a striking effect on the incidence
and latency of the disease.
To test if the increase in the dose of the PMLRARa
oncoprotein would have similar effects, we compared the
LFS and the incidence of leukemia between hCG-
PMLRARa1/2 and hCG-PMLRARa1/1 TM (Fig. 1,
b–d). LFS 6 SD of the hCG-PMLRARa1/1PML1/1,
hCG-PMLRARa1/1PML1/2, and hCG-PMLRARa1/1
PML2/2 mutants was of 439.4 6 22.6, 335 6 19.5, and
315 6 19.5 d, respectively (Fig. 1, b–d). Therefore, regard-
less of the PML dose, the LFS was significantly shorter in
the hCG-PMLRARa1/1 TM compared with the hCG-
PMLRARa1/2 TM. Accordingly, the incidence of leuke-
mia in the first year of life was significantly higher in
the hCG-PMLRARa1/1 compared with the hCG-
PMLRARa1/2 TM in all the PML subgroups (25.8, 52,
and 60% in the PML1/1, PML1/2, and PML2/2 sub-
groups, respectively). The differences in the LFS and leu-
kemia incidence were not significant between the hCG-
PMLRARa1/1PML1/2 and the hCG-PMLRARa1/1
PML2/2 mice. The inactivation of PML did not change
the morphology (Fig. 1 e) or the immunophenotypic fea-
tures of the leukemic cells (data not shown) in hCG-
PMLRARa1/2 or hCG-PMLRARa1/1 TM. In addition,
the hematological parameters of the peripheral blood at the
disease onset were similar between the six analyzed groups
(data not shown). The fact that the increase in the PML-
RARa dose further accelerated leukemia onset and pene-
trance even in a PML2/2 background suggests that the on-
coprotein is not solely affecting the PML pathway and is in
agreement with the notion that the fusion protein can also
interfere with the RARa/retinoid X receptor (RXR)
pathway.
As2O3, a chemical used in traditional Chinese medicine,
induces complete remission in about 90% of t(15;17) APL
(17). This drug causes the degradation of PMLRARa and
PML proteins, as well as the reconstitution of the normal
PML-NB pattern (18–20). In vitro studies demonstrated
that As2O3 also induces the relocalization of PML into the
PML-NB, suggesting that the antileukemic and proapop-
totic action of As2O3 may depend on PML expression (18).
Therefore, we tested whether the inactivation of PML
would impair the in vivo response to As2O3. We treated
leukemic hCG-PMLRARa1/2PML1/1 (n 5 6) and hCG-
PMLRARa1/2PML2/2 ( n  5 3) with 2.5 mg of As2O3
(Sigma-Aldrich) per gram of body weight daily, intraperi-
toneally for 3 wk, a regimen previously shown to be effec-
tive in the treatment of leukemia in hCG-PMLRARa TM
(20). Regardless of the presence of PML, As2O3 induced
disappearance of circulating leukemic blasts, normalization
of the hemoglobin levels and platelet counts, as well as the
reduction of promyelocytes in the BM to ,5%, thus dem-
onstrating that As2O3 can induce remission in both hCG-
PMLRARa1/2PML1/1 and hCG-PMLRARa1/2PML2/2
leukemic mice. Furthermore, there was no significant dif-
ference in LFS between PML2/2 and PML1/1 leukemic
TM treated with As2O3 (PML1/1: 36.7 d, 95% confidence
interval (C.I.): 29.5–43.9 d; PML2/2: 42 d 95% C.I.: 30.9–
53 d). In both groups, death was preceded by disease re-
lapse and the mice did not receive a second course of treat-
ment. The fact that the antileukemic activity of As2O3 is
independent of the presence of PML corroborates the study
by Wang et al. demonstrating that this drug inhibits growth
and induces apoptosis in both PML2/2 and PML1/1 mu-
rine embryonic fibroblasts and hematopoietic progenitors
(21).
We next tested whether PML would play a role in antag-
onizing neu-induced breast tumorigenesis by analyzing the
effect of PML inactivation in MMTV/neu TM (14). In
NIH3T3 cells, PML can antagonize oncogenesis by neu
and in fibroblasts it controls cellular senescence induced by
oncogenic Ras (7, 10). neu oncogenic activation can occur
through point mutations in the transmembrane domain,
deletion of the extracellular domain, or overexpression (22–
26). Overexpression and amplification of the neu protoon-
cogene have been implicated in human breast cancer patho-
genesis (25). Overexpression of neu protein may in fact be
the primary mechanism contributing to human breast can-
cer, as neu activating mutations were not identified in pri-
mary cancer biopsy samples (26). MMTV/neu TM develop
mammary tumors after a long latency (14; Fig. 2 a). Surpris-
ingly, PML inactivation did not modify the frequency, the
latency, the size of breast tumors, or the frequency of meta-
static involvement in MMTV/neu TM (Fig. 2 a). The
mean TFS 6 SD in PML1/1 group was of 568 6 35 d; in
the PML1/2 mice: 567 6 36 d; and in the PML2/2 mice:
590 6 26.8 d (P 5 0.94). All together, these results demon-
strate that in vivo PML plays a selective tumor suppressive
role antagonizing leukemogenesis by PMLRARa, but not
neu-induced mammary tumorigenesis.
PML can control cellular differentiation upon stimuli
such as RA (1, 12, 27), programmed cell death, as well as
cellular proliferation and senescence (10–12). Therefore,
we evaluated through which mechanisms PML would an-
tagonize oncogenesis and if and to which extent these pro-
cesses would be affected in the two TM models of neopla-
sia. In the breast tumors from MMTV/neu TM, apoptosis
was virtually undetectable in both PML1/1 and PML2/2
backgrounds, as analyzed by TUNEL (,1 in 400 cells; n 5
3 per genotype; Fig. 2 b). By contrast, cells from breast tu-
mor samples from the MMTV/neu/PML1/1 and MMTV/
neu/PML2/2 mice were found in active proliferation, but,
surprisingly, no differences were detected in the percentage
of Ki671 cells between the two PML genotypes (n 5 3 per
genotype; mean 6 SD: 30.5% 6 7.6 [PML1/1] and 27% 6525 Rego et al.
Figure 2. PML inactivation does not affect tumorigenesis in MMTV/neu TM. (a) MMTV/neu TM were mated with PML2/2 mice and their proge-
nies monitored for the incidence of breast tumors. The various genotypes and the numbers of mice analyzed are indicated (PML1/1, red line; PML1/2,
black line; PML2/2, green line). A similar frequency and TFS was observed in the MMTV/neu TM regardless of the PML genotype. (b and c) Assess-
ment of apoptosis (TUNEL) and proliferation (Ki67 staining) in breast tumors from MMTV/neu/PML1/1 and MMTV/neu/PML2/2 mice. Apoptotic
cells are virtually absent in these tumors (,1/400 cells scored in both genotypes: see indents) whereas numerous proliferating cells are detected in com-
parable numbers regardless of the PML background. Arrows show examples of positively stained cells. (d) PML is expressed in breast tumors from
MMTV/neu TM. Immunostaining with an anti-PML Ab of breast tumor frozen sections from MMTV/neu TM shows the characteristic PML nuclear
speckled pattern. Original magnification: 3400.526 PML in Tumor Suppression
4.8 [PML2/2] Ki671 cells; Fig. 2 b). This is in spite of the
fact that PML is expressed at high levels not only in breast
epithelium, but also in breast tumor samples (n 5 3 per
genotype; Fig. 2 b, and not shown). Thus, surprisingly, in a
tumor model in which increased cellular proliferation ap-
pears to be the main pathogenic event, PML inactivation
does not enhance the main oncogenic effect of neu, in
agreement with the fact that incidence latency and tumor
burden are unaffected in a PML2/2 background.
By contrast, PML heterozygosity or complete PML
inactivation dramatically accelerated leukemogenesis in
hCG-PMLRARa TM. Therefore, we investigated whether
this would affect the ability of hemopoietic cells, before
leukemia onset, to respond to growth inhibitory, differ-
entiating, and proapoptotic stimuli. At first, we studied the
effects of vitamin D3 and RA on the ability of BM he-
mopoietic precursors from the various mutants to form
myeloid colonies in a methylcellulose assay and mature
myeloid cells in liquid cultures. In these ex vivo assays, vi-
tamin D3 is a potent growth inhibitory molecule and a
modest differentiating agent (28, 29), whereas RA is an ef-
fective inducer of myeloid terminal differentiation (1, 12,
27). In the absence of vitamin D3 or RA and in standard
cytokine concentrations (see Materials and Methods), he-
mopoietic precursors from the various mutant mice gener-
ated similar numbers of erythroid and myeloid colonies
Figure 3. PML inactivation impairs the growth inhibi-
tory and differentiating activities of vitamin D3 (Vit. D)
and RA in BM cells from hCG-PMLRARa1/2 TM. He-
mopoietic cells from WT (white bars), PML2/2 (dotted
bar), hCG-PMLRARa1/2PML1/1 (black bar), and hCG-
PMLRARa1/2PML2/2 (gray bar) mice were cultured in
semisolid media (a and c) or in liquid media (b and d) in
the presence or absence of vitamin D3 (1029 M) or RA
(1027 M). The number of myeloid colonies (CFU-GM)
formed in methylcellulose (a and c) and the expression of
CD11b in liquid cultures (b and d) were analyzed after 7
and 3 d, respectively. The results are reported as percent-
ages observed in treated samples relative to controls. For
either a, b, c, or d, one experiment performed in triplicate,
out of three independent experiments with similar results,
is shown (Materials and Methods).
Figure 4. PML inactivation
enhances the protection from
Fas-induced apoptosis in BM
cells from hCG-PMLRARa1/2
TM. BM cells from mice of indi-
cated genotypes were cultured in
liquid media (a) or semisolid me-
dia (b) in the presence or absence
of 100 ng of anti-Fas Ab. (a) The
number of apoptotic cells in the
liquid culture assay was deter-
mined after 24 h by staining with
propidium iodide (PI) and an-
nexin V. Histogram bars repre-
sent the percentage of apoptotic
cells induced by anti-Fas treat-
ment. The mean percentage of
apoptotic cells in WT cultures is presented as 100%. Illustrative dot plots from flow cytometric analyses of Fas-stimulated BM cultures from mice of indi-
cated genotypes are shown in the right panel. (b) CFU-GM from in vitro methylcellulose colony assays were scored at day 7. The results are reported as
the percentage of myeloid colonies observed in treated samples relative to controls. For both a and b, one experiment performed in triplicate, out of three
independent experiments with similar results, is shown (Materials and Methods).527 Rego et al.
(data not shown). As expected, in BM cells from WT mice,
vitamin D3 (1029 M) and RA (1027 M) caused a decrease
and an increase in the number of CFU-GM colonies, re-
spectively. The growth inhibitory activity of vitamin D3
was already impaired in hemopoietic precursors from
PMLRARa1/2PML1/1 mice. Compared with BM cells
from WT mice, BM cells from PMLRARa1/2PML1/1
generated, in fact, a significantly higher number of CFU-
GM colonies (P , 0.001) in the methylcellulose assay. The
ability of vitamin D3 to induce terminal myeloid differenti-
ation (CD11b1 cells) in the liquid BM cultures was also
markedly reduced (P 5 0.04; Fig. 3, a and b). Similarly,
PML inactivation resulted in impaired response to vitamin
D3 (Fig. 3, a and b). Moreover, the inactivation of PML in
BM cells from PMLRARa TM resulted in a further en-
hancement of the unresponsiveness to vitamin D3 in both
the in vitro colony (P 5 0.01) and in the liquid culture
(P 5 0.009) assays (Fig. 3, a and b).
The differentiating effect of RA was significantly re-
duced in BM cells from PML2/2 and PMLRARa1/2
PML1/1 mice (P 5 0.001 and P , 0.001, respectively; Fig.
3, c and d). Furthermore, when treated with RA, BM cells
from PMLRARa1/2PML2/2 mice generated a signifi-
cantly lower (P 5 0.001) number of CFU-GM colonies
compared with BM cells from PMLRARa1/2PML1/1
mice (Fig. 3 c). Similar effects were noticed in the liquid
BM culture assay where RA increased the percentage of
CD11b1 cells in culture from WT mice, whereas this effect
was greatly reduced in cells from PML2/2 (P 5 0.001) and
in PMLRARa1/2PML1/1 mice (P 5 0.001; Fig. 3 d). In
complete agreement with the results obtained in the colony
assay, the inactivation of PML caused a further significant
impairment in the ability of PMLRARa cells to respond to
RA in the liquid BM culture assay (P 5 0.007; Fig. 3 d).
Thus, the inactivation of the PML pathway and/or the
presence of PMLRARa block the response of myeloid he-
mopoietic progenitors to the growth inhibitory and differ-
entiating ability of vitamin D3 and RA.
PML inactivation results in unresponsiveness to many
apoptotic stimuli including Fas (11). Therefore, we used
the response of BM cells to an activating anti-Fas mAb as a
read out of the possible survival advantage observed in the
BM cells from the various mutant mice before leukemia
occurrence (see Materials and Methods). Under these ex-
perimental conditions, in WT BM cells cultures, 73.7 6
11.6% of the cells underwent apoptosis upon anti-Fas treat-
ment. Compared with the WT, the percentage of apop-
totic cells upon Fas stimulation was significantly reduced in
the PML2/2 ( P  , 0.001) and in the PMLRARa1/2
PML1/1 (P , 0.001) mutants (Fig. 4 a). PML inactivation
in PMLRARa TM resulted in a significant further de-
crease in the number of apoptotic cells (P 5 0.004). As ex-
pected, the anti-Fas mAb also induced a decrease in the
number of CFU-GM colonies from WT BM cells in in
vitro colony assays. Once again, compared with WT cells,
BM cells from PML2/2 (P 5 0.02) and PMLRARa1/2
PML1/1 (P , 0.001) mutants showed a marked protection
from Fas-induced apoptosis. Moreover, the number of
CFU-GM colonies was significantly higher in the PML-
RARa PML2/2 mice (P 5 0.006).
In summary, the results reported here conclusively dem-
onstrate in vivo and in relevant disease contexts that: (a)
PML acts as a tissue specific tumor suppressor by rendering
the cells sensitive to proapoptotic and differentiating stim-
uli. (b) PML haploinsufficiency and its functional impair-
ment by PMLRARa are critical events in pathogenesis of
APL-like leukemia in mice, thus indicating that the loss of
one PML allele, as a consequence of the t(15;17), may be a
critical event in human APL. (c) The acquisition of survival
advantage is a critical event in the multistep process toward
APL leukemogenesis. (d) Although PML can control se-
nescence and cell proliferation and in vitro tumorigenesis
by neu (7, 10), in vivo PML inactivation does not play a
significant role in neu-induced breast tumorigenesis.
PML may regulate RARa/RXR transcription function
by participating in this complex as a ligand-dependent tran-
scriptional coactivator (27). By contrast, the mechanisms by
which PML may regulate vitamin D response are yet un-
clear. Vitamin D receptor (VDR) bind DNA predomi-
nantly in its heterodimeric form with RXR (30). Binding
of the ligand to the VDR leads to the recruitment of coac-
tivators such as steroid receptor coactivator (SRC)/p160
and the vitamin D receptor interacting protein (DRIP; also
known as thyroid hormone receptor–associated protein
[TRAP], activator recuited cofactor [ARC], and negative
regulator of activated transcription [NAT]) coactivator
complex (31). PML can be part of the DRIP complex asso-
ciated with RARa/RXR (27). Thus, it is tempting to
speculate that PML may participate in VDR/RXR com-
plex as well. As PMLRARa can heterodimerize with and
sequester PML (5, 32), both a reduction in the dose of
PML or an increase in the dose of PMLRARa could result
in a striking increase in the dominant negative action of the
oncoprotein on PMLRARa/RXR and PML VDR/RXR
pathways (27).
In an accompanying study in this issue by Kogan et al.
(33), leukemogenesis in a PMLRARa transgenic model is
accelerated by coexpression of the BCL-2 protooncogene,
which lends to the hemopoietic progenitors a survival ad-
vantage. PML has been implicated in p53-dependent and
-independent pathways for apoptosis (6, 11). As a result,
Pml2/2 cells are resistant to multiple proapoptotic stimuli
such as Fas, DNA damage, ceramide, TNF, and IFN.
Thus, PMLRARa can act as antiapoptotic oncogene possi-
bly through its ability to antagonize the function of PML.
In agreement with this tenet, PML inactivation exacerbates
the antiapoptotic activity of PMLRARa and accelerates
leukemogenesis. Thus, protection from apoptosis may be a
key event in APL pathogenesis.
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